medigraphic.com
SPANISH

Annals of Hepatology

Órgano Oficial de la Asociación Mexicana de Hepatología
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2012, Number 1

<< Back Next >>

Ann Hepatol 2012; 11 (1)

Is it appropriate to study blood ghrelin and obestatin in non-alcoholic fatty liver disease (NAFLD) without using protease inhibitors?

Aydin S
Full text How to cite this article

Language: English
References: 14
Page: 145-146
PDF size: 51.80 Kb.


Key words:

No keywords

Text Extraction

To the Editor
I have read the article about the changes in ghrelin and obestatin levels authored by Dr. Gutierrez- Grobe, et al. and published in Annals of Hepatology with great interest. Ghrelin and obestatin are peptide hormones which are easily broken down by proteases


REFERENCES

  1. Gutierrez-Grobe Y, Villalobos-Blasquez I, Sánchez-Lara K, Villa AR, Ponciano-Rodríguez G, Ramos MH, Chavez-Tapia NC, Uribe M, Méndez-Sánchez N. High ghrelin and obestatin levels and low risk of developing fatty liver. Ann Hepatol 2010; 9: 52-7.

  2. Hosoda H, Doi K, Nagaya N, Okumura H, Nakagawa E, Enomoto M, Ono F, Kangawa K. Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples. Clin Chem 2004; 50: 1077-108.

  3. Blatnik M, Soderstrom CI. A practical guide for the stabilization of acylghrelin in human blood collections. Clin Endocrinol 2011; 74: 325-31.

  4. Available from: http://www.phoenixpeptide.com.

  5. Available from: http://www.bioquote.com.

  6. Aydin S, Sahin I, Demirel U, Aksoy A. To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease? Metabolism 2011; 60: 1.

  7. Aydin S. Discovery of ghrelin hormone: research and clinical applications. Turk J Biochem 2007; 32: 76-89.

  8. Rawlings ND, Barrett AJ, Bateman A. MEROPS: the peptidase

  9. database. Nucleic Acids Res 2010; 38: 227-33.

  10. Gutierrez-Grobe Y, et al. High ghrelin and obestatin levels and low risk of developing fatty liver. Annals of Hepatology 2010; 9: 52-7.

  11. Blatnik M, Soderstrom CI. A practical guide for the stabilization of acylghrelin in human blood collections. Clinical endocrinol 2011; 74: 325-31.

  12. Chavez-Tapia NC, et al. Smoking is not associated with nonalcoholic fatty liver disease. World J Gastroenterol 2006; 12: 5196-200.

  13. Mendez-Sanchez N, et al. Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol 2005; 11: 1737-41.

  14. French BA, et al. The immunoproteasome in steatohepatitis: its role in Mallory-Denk body formation. Experimental and molecular pathology 2011; 90: 252-6.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Ann Hepatol. 2012;11